Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Probiodrug in Alzheimer’s Assay Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Probiodrug in Alzheimer’s Assay Alliance

Will validate assays to support clinical trials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has entered into a collaboration with Probiodrug AG, a biopharmaceutical company focused on drug development for major age-related diseases. Evotec will set up and validate assays to support preclinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer’s disease (AD). Glutaminyl cyclase is a novel enzyme target discovered by Probiodrug, and plays a role in the pathogenesis of AD as well as potentially other diseases.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are pleased to enter this collaboration with Probiodrug to use our first class assay development capabilities to support the preclinical and clinical development of QC inhibitors in Alzheimer’s disease and other indications. This is a good example of how Evotec can support biotech companies with their specific drug discovery needs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics